Management of metabolic syndrome: statins.
Individuals who have the metabolic syndrome are at increased risk for cardiovascular disease. Combined dyslipidemia is an important component of metabolic syndrome, contributing to excess cardiovascular risk. Lifestyle and pharmacologic interventions are warranted for effective management of this syndrome. This article discusses the current evidence supporting the use of statins and their beneficial impact on lipid and nonlipid aspects of metabolic syndrome-related pathology.
Xydakis
Antonios M
AM
Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Ballantyne
Christie M
CM
D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000188:drug therapy*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors